Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol 2011; 17(41): 4563-4571 [PMID: 22147961 DOI: 10.3748/wjg.v17.i41.4563] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] Open

For:	Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol 2011; 17(41): 4563-4571 [PMID: 22147961 DOI: 10.3748/wjg.v17.i41.4563] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] Open

Number

Cited by Other Article(s)

Chaudhuri AG, Samanta S, Dey M, Raviraja NS, Dey S. Role of Alpha-Fetoprotein in the Pathogenesis of Cancer. J Environ Pathol Toxicol Oncol 2024;43:57-76. [PMID: 38505913 DOI: 10.1615/jenvironpatholtoxicoloncol.2023049145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/21/2024] Open

Tzouanas CN, Sherman MS, Shay JE, Rubin AJ, Mead BE, Dao TT, Butzlaff T, Mana MD, Kolb KE, Walesky C, Pepe-Mooney BJ, Smith CJ, Prakadan SM, Ramseier ML, Tong EY, Joung J, Chi F, McMahon-Skates T, Winston CL, Jeong WJ, Aney KJ, Chen E, Nissim S, Zhang F, Deshpande V, Lauer GM, Yilmaz ÖH, Goessling W, Shalek AK. Chronic metabolic stress drives developmental programs and loss of tissue functions in non-transformed liver that mirror tumor states and stratify survival. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.11.30.569407. [PMID: 38077056 PMCID: PMC10705501 DOI: 10.1101/2023.11.30.569407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/18/2023]

Abstract

Under chronic stress, cells must balance competing demands between cellular survival and tissue function. In metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH), hepatocytes cooperate with structural and immune cells to perform crucial metabolic, synthetic, and detoxification functions despite nutrient imbalances. While prior work has emphasized stress-induced drivers of cell death, the dynamic adaptations of surviving cells and their functional repercussions remain unclear. Namely, we do not know which pathways and programs define cellular responses, what regulatory factors mediate (mal)adaptations, and how this aberrant activity connects to tissue-scale dysfunction and long-term disease outcomes. Here, by applying longitudinal single-cell multi -omics to a mouse model of chronic metabolic stress and extending to human cohorts, we show that stress drives survival-linked tradeoffs and metabolic rewiring, manifesting as shifts towards development-associated states in non-transformed hepatocytes with accompanying decreases in their professional functionality. Diet-induced adaptations occur significantly prior to tumorigenesis but parallel tumorigenesis-induced phenotypes and predict worsened human cancer survival. Through the development of a multi -omic computational gene regulatory inference framework and human in vitro and mouse in vivo genetic perturbations, we validate transcriptional (RELB, SOX4) and metabolic (HMGCS2) mediators that co-regulate and couple the balance between developmental state and hepatocyte functional identity programming. Our work defines cellular features of liver adaptation to chronic stress as well as their links to long-term disease outcomes and cancer hallmarks, unifying diverse axes of cellular dysfunction around core causal mechanisms.

Collapse

Affiliation(s)

Constantine N. Tzouanas Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA These authors contributed equally
Marc S. Sherman Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA These authors contributed equally
Jessica E.S. Shay David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Alcohol Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA These authors contributed equally
Adam J. Rubin Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA
Benjamin E. Mead Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA
Tyler T. Dao Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
Titus Butzlaff Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Miyeko D. Mana David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA School of Life Sciences, Arizona State University, Tempe, AZ, USA
Kellie E. Kolb Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA
Chad Walesky Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Brian J. Pepe-Mooney Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA
Colton J. Smith Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Sanjay M. Prakadan Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA
Michelle L. Ramseier Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA
Evelyn Y. Tong Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA
Julia Joung Broad Institute of MIT and Harvard, Cambridge, MA, USA Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA Department of Brain and Cognitive Science, MA, Cambridge, MA, USA McGovern Institute for Brain Research at MIT, Cambridge, MA, USA Howard Hughes Medical Institute, MIT, Cambridge, MA, USA Whitehead Institute for Biomedical Research, Cambridge, MA, USA
Fangtao Chi David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
Thomas McMahon-Skates Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Carolyn L. Winston Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Woo-Jeong Jeong Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA, USA
Katherine J. Aney Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA, USA
Ethan Chen Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA, USA
Sahar Nissim Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA, USA Gastroenterology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Feng Zhang Broad Institute of MIT and Harvard, Cambridge, MA, USA Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA Department of Brain and Cognitive Science, MA, Cambridge, MA, USA McGovern Institute for Brain Research at MIT, Cambridge, MA, USA Howard Hughes Medical Institute, MIT, Cambridge, MA, USA
Vikram Deshpande Department of Pathology, Massachusetts General Hospital, Boston, MA
Georg M. Lauer Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA
Ömer H. Yilmaz David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA Department of Pathology, Massachusetts General Hospital, Boston, MA These senior authors contributed equally
Wolfram Goessling Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA Dana-Farber Cancer Institute, Boston, MA, USA Harvard Stem Cell Institute, Cambridge, MA, USA Developmental and Regenerative Biology Program, Harvard Medical School, Boston, MA, USA These senior authors contributed equally
Alex K. Shalek Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Cambridge, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA David H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA These senior authors contributed equally

Collapse

Paskeh MDA, Ghadyani F, Hashemi M, Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S, Entezari M, Goharrizi MASB, Salimimoghadam S, Aref AR, Kalbasi A, Rajabi R, Rashidi M, Taheriazam A, Sethi G. Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Pharmacol Res 2023;187:106553. [PMID: 36400343 DOI: 10.1016/j.phrs.2022.106553] [Citation(s) in RCA: 31] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 11/09/2022] [Accepted: 11/10/2022] [Indexed: 11/17/2022]

Affiliation(s)

Mahshid Deldar Abad Paskeh Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Fatemeh Ghadyani Farhikhtegan Medical Convergence sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Mehrdad Hashemi Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Alireza Abbaspour Cellular and Molecular Research Center,Qazvin University of Medical Sciences, Qazvin, Iran
Amirhossein Zabolian Resident of department of Orthopedics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Salar Javanshir Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Mehrnaz Razzazan Medical Student, Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
Sepideh Mirzaei Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran
Maliheh Entezari Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Mohammad Ali Shekhi Beig Goharrizi Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Shokooh Salimimoghadam Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran
Amir Reza Aref Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Translational Sciences, Xsphera Biosciences Inc. 6, Tide Street, Boston, MA 02210, USA
Alireza Kalbasi Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Romina Rajabi Faculty of Veterinary Medicine, Islamic Azad University, Science and Research Branch, Tehran, Iran.
Mohsen Rashidi Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Afshin Taheriazam Farhikhtegan Medical Convergence sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Orthopedics, Faculty of medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Gautam Sethi Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; NUS Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.

Collapse

Chen J, Lai L, Luo J, Wang H, Li M, Huang M. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study. BMC Cancer 2022;22:1242. [PMID: 36451104 PMCID: PMC9714197 DOI: 10.1186/s12885-022-10361-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Accepted: 11/23/2022] [Indexed: 12/05/2022] Open

Abstract

BACKGROUND

Conventional-transarterial chemoembolization (C-TACE) was proven to improve overall survival (OS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT), drug-eluting microsphere-TACE (DEM-TACE) was supposed to provide more benefit than C-TACE in this respect.

PURPOSE

To compare the safety and efficacy between DEM-TACE and C-TACE as the initial treatment in HCC patients with PVTT and to identify prognostic factors of OS.

METHODS

The medical records of advanced HCC patients with PVTT who underwent DEM-TACE or C-TACE as the initial thearpy from September 2015 with mean follow-up time 14.9 ± 1.2 (95% CI 12.6-17.2) months were retrospectively evaluated. A total of 97 patients were included, 49 patients in the DEM-TACE group and 48 in the C-TACE group. Adverse events (AEs) related to TACE were compared. Tumor and PVTT radiologic response, time to tumor progression (TTP) and OS were calculated and compared in both groups.

RESULTS

Patients in DEM-TACE group had a better radiologic response (Tumr response: 89.8% vs. 75.0%; PVTT response: 85.7% vs. 70.8%; overall response: 79.6% vs. 58.3%, P = 0.024) and longer TTP (7.0 months vs. 4.0 months, P = 0.040) than patients in C-TACE group. A lower incidence of abdominal pain was found in the DEM-TACE group than in C-TACE group (21 vs. 31, P = 0.032), but there were no significant differences between DEM-TACE and C-TACE patients in any other AEs reported. When compared to C-TACE, DEM-TACE also showed significant OS benefits (12.0 months vs. 9.0 months, P = 0.027). DEM-TACE treatment, the absence of arterioportal shunt (APS), lower AFP value and better PVTT radiologic response were the independent prognostic factors for OS in univariate/multivariate analyses, which provided us with a guide for better patient selection.

CONCLUSIONS

Based on our retrospective study, DEM-TACE can be performed safely and might be superior to C-TACE as the initial treatment for HCC patients with PVTT.

TRIAL REGISTRATION

Retrospectively registered.

Collapse

Zam W, Assaad A. Chimeric antigen receptor T-cells (CARs) in cancer treatment. Curr Mol Pharmacol 2021;15:532-546. [PMID: 34382510 DOI: 10.2174/1874467214666210811150255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 04/27/2021] [Accepted: 05/17/2021] [Indexed: 11/22/2022]

Alam S, Nasreen S, Ahmad A, Darokar MP, Khan F. Detection of Natural Inhibitors against Human Liver Cancer Cell Lines through QSAR, Molecular Docking and ADMET Studies. Curr Top Med Chem 2021;21:686-695. [PMID: 33280598 DOI: 10.2174/1568026620666201204155830] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 08/22/2020] [Accepted: 08/31/2020] [Indexed: 11/22/2022]

Li W, Liu K, Chen Y, Zhu M, Li M. Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Curr Med Chem 2021;28:1126-1142. [PMID: 32729413 DOI: 10.2174/0929867327999200729151247] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 07/04/2020] [Accepted: 07/11/2020] [Indexed: 01/30/2023]

Zhang C, Zhang J, Wang J, Yan Y, Zhang C. Alpha-fetoprotein accelerates the progression of hepatocellular carcinoma by promoting Bcl-2 gene expression through an RA-RAR signalling pathway. J Cell Mol Med 2020;24:13804-13812. [PMID: 33090723 PMCID: PMC7753843 DOI: 10.1111/jcmm.15962] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Revised: 08/19/2020] [Accepted: 08/31/2020] [Indexed: 12/25/2022] Open

Kim H, Lee SJ, Yoon M. Alpha-fetoprotein is correlated with intrahepatic recurrence of hepatocellular carcinoma after a hepatectomy. Ann Surg Treat Res 2020;98:168-176. [PMID: 32274364 PMCID: PMC7118319 DOI: 10.4174/astr.2020.98.4.168] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 11/19/2019] [Accepted: 02/07/2020] [Indexed: 12/28/2022] Open

Abstract

Purpose

Intrahepatic recurrence has a significant effect on the survival of hepatocellular carcinoma (HCC) patients. We aimed to determine if there are useful indicators in predicting the recurrence of liver cancer after a hepatic resection.

Methods

We retrospectively reviewed medical records of 210 HCC patients who underwent hepatectomy between January 2009 and December 2015. We examined clinic-pathological variables comparing 2 groups of HCC patients, either intrahepatic recurrence or not.

Results

We divided 184 patients into 2 groups; 94 patients (51.1%) with intrahepatic recurrence and 90 patients (48.9%) without intrahepatic recurrence. Multivariate analysis showed operation type, preoperative α-FP, postoperative protein induced by vitamin K absence-II (PIVKA-II) elevation, and multiple tumor number were closely associated with intrahepatic recurrence. The preoperative PIVKA-II level was not statistically significant in postoperative intrahepatic recurrence rate. The recurrence rate was 46.2% in 132 of 184 cases of α-FP < 100 ng/mL group. Of the 184 cases, α-FP 100-200 ng/mL were 14 cases (12 cases recurred (85.7%)). Alpha-fetoprotein > 200 ng/mL was 38 of 184 cases, 21 of which recurred (55.3%). According to the multivariate analysis, OR ratio was 8.003 (95% confidence interval [CI], 1.549-41.353) in the α-FP 100-200 ng/mL group and 1.867 (95% CI, 0.784-4.444) in α-FP 200 ng/mL or higher group (P = 0.013). Three-year survival rate of intrahepatic recurrence patients was 80.7%, 3-year survival rate of no intrahepatic recurrence patients was 95.0%.

Conclusion

The intrahepatic recurrence rates were high in the group preop α-FP over 100 ng/mL. Close observation is needed. Prospective study for α-FP genes of HCC patients should be planned for predicting intrahepatic recurrence after hepatectomy.

Collapse

Xing H, Qiu H, Ding X, Han J, Li Z, Wu H, Yan C, Li H, Han R, Zhang H, Li C, Wang M, Wu M, Shen F, Zheng Y, Yang T. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma. Biomark Med 2019;13:545-555. [PMID: 31140827 DOI: 10.2217/bmm-2018-0414] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open

Affiliation(s)

Hao Xing Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Haibo Qiu Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Xuemei Ding Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Jun Han Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Zhenli Li Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Han Wu Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Cunling Yan Department of Clinical Laboratory, Peking University First Hospital, Beijing, PR China
Huijun Li Department of Laboratory Medicine, Huazhong University of Science and Technology, Tongji Medical College, Tongji Hospital, Wuhan, PR China
Ruilin Han Department of Clinical Laboratory, Peking University First Hospital, Beijing, PR China
Han Zhang Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Chao Li Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Mingda Wang Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Mengchao Wu Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Feng Shen Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China
Yijie Zheng Medical Scientific Affairs, Abbott Diagnostics, Shanghai, PR China
Tian Yang Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, PR China

Collapse

Huang YL, Wu JR, Fang M, Zhao HL, Liu ZM, Ye J, Huang LS, Zhu B. The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e15090. [PMID: 30946366 PMCID: PMC6456153 DOI: 10.1097/md.0000000000015090] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open

Abstract

The aim of this study was to evaluate the effects of polymorphisms in excision repair cross-complementation group 1 (ERCC1) and alpha-fetoprotein (AFP) genes and their haplotypes on the susceptibility to hepatocellular carcinoma (HCC), and to decipher the association between single-nucleotide polymorphisms (SNPs) and clinicopathologic characteristics of HCC.Peripheral blood DNA was extracted from 206 subjects. SNaPshot technique was used for genotyping 5 SNP sites of the ERCC1 rs735482, rs1046282, rs3212948, and AFP rs737241, rs4024 genotypes. Chi-squared test and logistic regression model were used to analyze the relationship of different genotypes or haplotype and the susceptibility and clinicopathologic characteristics of HCC.The frequency of GG.GA and AA genotypes at the AFP rs737241 site in the case and control groups showed statistically significant differences (P < .05). The risk of HCC in subjects carrying mutated allele A (GA+AA) was increased by 0.543-times (P < .05) compared to that in the subjects with the GG genotype. Significant differences were observed in the linkage disequilibrium between 2 of the five SNPs (P < .05); the frequency of ERCC1 C-C and AFP A-A haplotypes was significantly lower in the case group than in the control group (P < .05). The results of clinicopathologic analysis showed that A allele at the rs737241 locus could increase the expression level of AFP (P = .007), the rs1046282 mutation C allele could increase the AFP expression level (P = .011), rs4024 locus mutation A allele could reduce the risk of vascular invasion (P = .013), rs3212948 locus mutation T allele could reduce the differentiation of liver cancer (P = .022), rs1046282 locus C allele could reduce the DNA load of hepatitis B virus (P = .035), and rs735482 A allele could increase the tumor size in HCC (P = .037).The SNPs in rs737241 for AFP gene may correlate with the occurrence of HCC. The SNPs in ERCC1 and AFP genes may affect the prognosis of HCC, offering reliable information for early prediction of tumor progression and diagnosis of HCC.

Collapse

Wang S, Zhu M, Wang Q, Hou Y, Li L, Weng H, Zhao Y, Chen D, Ding H, Guo J, Li M. Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death Dis 2018;9:1027. [PMID: 30301886 PMCID: PMC6177398 DOI: 10.1038/s41419-018-1036-5] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 08/30/2018] [Accepted: 09/03/2018] [Indexed: 02/07/2023]

Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases 2018;6:110-120. [PMID: 29988930 PMCID: PMC6033749 DOI: 10.12998/wjcc.v6.i6.110] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 05/11/2018] [Accepted: 05/30/2018] [Indexed: 02/05/2023] Open

Zhu K, Huang J, Lai L, Huang W, Cai M, Zhou J, Guo Y, Chen J. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology 2018;288:300-307. [PMID: 29688153 DOI: 10.1148/radiol.2018172028] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]

Affiliation(s)

Kangshun Zhu From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Jingjun Huang From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Lisha Lai From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Wensou Huang From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Mingyue Cai From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Jingwen Zhou From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Yongjian Guo From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)
Junwei Chen From the Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Rd, Guangzhou, Guangdong 510260, China (K.Z., J.H., W.H., M.C., J.Z., Y.G.); Department of Radiology, Guangzhou First Municipal People's Hospital, Guangzhou, China (L.L.); and Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (J.C.)

Collapse

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. Can J Gastroenterol Hepatol 2018;2018:9049252. [PMID: 29805966 PMCID: PMC5899840 DOI: 10.1155/2018/9049252] [Citation(s) in RCA: 212] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2017] [Revised: 01/25/2018] [Accepted: 03/18/2018] [Indexed: 02/06/2023] Open

Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Oncotarget 2018;8:408-417. [PMID: 27880724 PMCID: PMC5352129 DOI: 10.18632/oncotarget.13427] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Accepted: 11/11/2016] [Indexed: 02/06/2023] Open

Martínez-Mier G, Esquivel-Torres S, Nava-Lacorte A, Lajud-Barquín F, Zilli-Hernández S, Vázquez-Ramírez L. Correlation between preoperative serum alpha-fetoprotein levels and survival with respect to the surgical treatment of hepatocellular carcinoma at a tertiary care hospital in Veracruz, Mexico. REVISTA DE GASTROENTEROLOGÍA DE MÉXICO (ENGLISH EDITION) 2017. [DOI: 10.1016/j.rgmxen.2017.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open

Martínez-Mier G, Esquivel-Torres S, Nava-Lacorte A, Lajud-Barquín FA, Zilli-Hernández S, Vázquez-Ramírez LM. Correlation between preoperative serum alpha-fetoprotein levels and survival with respect to the surgical treatment of hepatocellular carcinoma at a tertiary care hospital in Veracruz, Mexico. REVISTA DE GASTROENTEROLOGÍA DE MÉXICO 2017;82:357-360. [PMID: 28893428 DOI: 10.1016/j.rgmx.2017.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Revised: 03/10/2017] [Accepted: 03/28/2017] [Indexed: 11/16/2022]

Ohkawa K, Asakura T, Tsukada Y, Matsuura T. Antibody to human α-fetoprotein inhibits cell growth of human hepatocellular carcinoma cells by resuscitating the PTEN molecule: in vitro experiments. Int J Oncol 2017;50:2180-2190. [PMID: 28498467 DOI: 10.3892/ijo.2017.3982] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2017] [Accepted: 04/10/2017] [Indexed: 11/06/2022] Open

Abstract

It has been proposed that α-fetoprotein (AFP) is a new member of the intracellular signaling molecule family of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway via interaction with the phosphatase and tensin homolog (PTEN). In this study, the effects of anti-human AFP antibody on the functions of PTEN were examined using an AFP-producing human hepatoma cell line. The antibody caused significant inhibition of cell growth, compared to a normal IgG control, with the accumulation of intracellular immune complexes followed by significant reduction of cytosolic functional AFP. Decrease in the amount of AKT phosphorylated on serine (S) 473 indicated that PI3K/AKT signaling was suppressed in the cells. S380-phosphorylated PTEN increased markedly by the second day after antibody treatment, with slight but significant increase in the PTEN protein level. Since phosphorylation at S380 is critical for PTEN stability, the increase in S380-phosphorylated PTEN indicated maintenance of the number of PTEN molecules and the related potential to control PI3K/AKT signaling. p53 protein (P53) significantly, but slightly increased during antibody treatment, because PTEN expression increased the stability and function of P53 via both molecular interactions. P53 phosphorylated at S20 or at S392 dramatically increased, suggesting an increase in the stability, accumulation and activation of P53. Glucose transporter 1 (GLUT1) increased immediately after antibody treatment, pointing to a deficiency of glucose in the cells. Immunofluorescence cytology revealed that antibody-treatment re-distributed GLUT1 molecules throughout the cytoplasm with a reduction of their patchy localization on the cell surface. This suggested that translocation of GLUT1 depends on the PI3K/AKT pathway, in particular on PTEN expression. Antibody therapy targeted at AFP-producing tumor cells showed an inhibitory effect on the PI3K/AKT pathway via the liberation, restoration and functional stabilization of PTEN. PTEN simultaneously induced both P53 activation and intracellular translocation of GLUT1, since these are closely associated with PTEN.

Collapse

Reim D, Choi YS, Yoon HM, Park B, Eom BW, Kook MC, Ryu KW, Choi IJ, Joo J, Kim YW. Alpha-fetoprotein is a significant prognostic factor for gastric cancer: Results from a propensity score matching analysis after curative resection. Eur J Surg Oncol 2017;43:1542-1549. [PMID: 28511775 DOI: 10.1016/j.ejso.2017.04.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Revised: 04/19/2017] [Accepted: 04/21/2017] [Indexed: 02/07/2023] Open

Abstract

BACKGROUND

Prognosis of alpha-fetoprotein positive gastric cancer (AFPP-GC) remains elusive so far due to disparities in cohort size and baseline characteristics in previous studies. A propensity score matching (PSM) analysis as well as multivariable model was performed for unbiased evaluation of the outcome in AFPGC.

METHODS

Among 3034 gastric cancer patients who underwent curative gastric cancer surgery (R0, M0) at the National Cancer Center, Korea between 2002 and 2007, we identified 97 patients being positive for AFP either by elevation of serum-AFP levels >10 μg/L or by immunohistochemical staining. Due to marked disparities in baseline characteristics and cohort size, propensity-score-matching was performed which matched 87 AFPP-GC patients to the same number of AFP-negative gastric cancer (AFPN-GC) patients. Baseline characteristics were compared using χ²-test. Survival curves were compared using the Kaplan-Meier-method and multivariable regression analysis was performed to evaluate the effect of AFP-positivity while adjusting the effects of confounding variables.

RESULTS

AFPP-GC and AFPN-GC patients revealed marked disparities in patient cohorts. After PSM, groups were balanced for age, sex, tumor size, BMI, tumor location, grade of differentiation, presence of lymphatic vessel infiltration (LVI), Lauren histologic type and stage distribution. In multivariable regression analysis of the PSM-groups, only AFP-positivity and pathologic stage were predictive for overall survival (HR 2.98, CI 95% {1.7-5.1}, p < 0.0001). Five-year-survival rates were significantly worse for AFPP-GC patients (57.9% vs. 76.1%, p = 0.014). Recurrence was significantly more frequent in AFPP-GC patients (p = 0.003).

CONCLUSION

AFP can be considered as an independent negative predictor of overall and recurrence-free survival in patients with gastric cancer.

Collapse

El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J 2017;5:227-235. [PMID: 28344790 PMCID: PMC5349365 DOI: 10.1177/2050640616659024] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 06/17/2016] [Indexed: 12/21/2022] Open

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52:512-519. [PMID: 27704266 PMCID: PMC5357473 DOI: 10.1007/s00535-016-1263-4] [Citation(s) in RCA: 235] [Impact Index Per Article: 33.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Accepted: 09/06/2016] [Indexed: 02/04/2023]

Abstract

BACKGROUND

Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular carcinoma (HCC).

METHODS

Patients with histologically/clinically confirmed advanced HCC who did not qualify for surgical resection or local therapies received lenvatinib at a dosage of 12 mg once daily (QD) in 28-day cycles. The primary efficacy endpoint was time to progression (TTP) per modified Response Evaluation Criteria in Solid Tumors v1.1; secondary efficacy endpoints included objective response rate (ORR), disease control rate (DCR), and overall survival (OS).

RESULTS

Between July 2010 and June 2011, 46 patients received lenvatinib at sites across Japan and Korea. The median TTP, as determined by independent radiological review, was 7.4 months [95 % confidence interval (CI): 5.5-9.4]. Seventeen patients (37 %) had partial response and 19 patients (41 %) had stable disease (ORR: 37 %; DCR: 78 %). Median OS was 18.7 months (95 % CI: 12.7-25.1). The most common any-grade adverse events (AEs) were hypertension (76 %), palmar-plantar erythrodysesthesia syndrome (65 %), decreased appetite (61 %), and proteinuria (61 %). Dose reductions and discontinuations due to AEs occurred in 34 (74 %) and 10 patients (22 %), respectively. Median body weight was lower in patients with an early (<30 days) dose withdrawal or reduction than in those without.

CONCLUSIONS

Lenvatinib 12-mg QD showed clinical activity and acceptable toxicity profiles in patients with advanced HCC, but early dose modification was necessary in patients with lower body weight. Further development of lenvatinib in HCC should consider dose modification by body weight. TRIAL REGISTRATION ID: www.ClinicalTrials.gov NCT00946153.

Collapse

Shen JY, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy. J Surg Res 2016;209:102-111. [PMID: 28032546 DOI: 10.1016/j.jss.2016.10.005] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Revised: 06/15/2016] [Accepted: 10/05/2016] [Indexed: 02/05/2023]

Abstract

BACKGROUND

Assessing the outcomes of surgeries for hepatocellular carcinoma (HCC) patients who exceed the Milan criteria is necessary. Some studies have demonstrated that preoperative or postoperative alpha fetoprotein (AFP) can predict HCC patients' prognoses.

METHODS

A total of 280 HCC patients who were positive for AFP and received curative resection were retrospectively analyzed. The patients were classified into three groups according to their preoperative and postoperative AFP levels (group A: normalized AFP; group B: AFP decreases >50%, but continued abnormality; and group C: AFP decreases <50%). Disease-free survival and overall survival rates were analyzed using the Kaplan-Meier method. The factors associated with AFP changes were evaluated by logistic regression.

RESULTS

AFP dynamic changes were independently associated with disease-free survival and overall survival rates. Group A had better 3- and 5-y survivals than groups B or C (58.7% and 39.5% versus 31.3% and 14.9% versus 17.1% and 8.8%, P < 0.001). Preoperative AFP, tumor differentiation, tumor diameter, microvascular invasion, and satellite nodules remained significant risk factors that were associated with AFP changes. Furthermore, in group A, the disappearances of AFP within and beyond 8 wk resulted in similar overall survival rates (P > 0.05). Among those with HCC recurrence, the patients treated with resurgery or radiofrequency ablation achieved the best recurrence to death survivals. Those treated with transcatheter arterial chemoembolization achieved the next best survivals.

CONCLUSIONS

AFP changes predicted the prognoses of patients with HCC beyond the predictions of the Milan criteria. Preoperative AFP (>400 ng/mL), tumor differentiation, tumor diameter, and satellite nodules were the risk factors related to AFP normalization. The regular follow-up and early detection of recurrent HCCs that are suitable for curative therapies, such as resurgery and radiofrequency ablation, might improve the prognoses. Other therapies, such as transcatheter arterial chemoembolization, might also be effective.

Collapse

Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res 2016;23:478-488. [PMID: 27535982 DOI: 10.1158/1078-0432.ccr-16-1203] [Citation(s) in RCA: 143] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 08/02/2016] [Accepted: 08/04/2016] [Indexed: 12/12/2022]

Affiliation(s)

Hong Liu Eureka Therapeutics Inc., Emeryville, California
Yiyang Xu Eureka Therapeutics Inc., Emeryville, California
Jingyi Xiang Eureka Therapeutics Inc., Emeryville, California
Li Long Eureka Therapeutics Inc., Emeryville, California
Shon Green Eureka Therapeutics Inc., Emeryville, California
Zhiyuan Yang Eureka Therapeutics Inc., Emeryville, California
Bryan Zimdahl Eureka Therapeutics Inc., Emeryville, California
Jingwei Lu Eureka Therapeutics Inc., Emeryville, California
Neal Cheng Eureka Therapeutics Inc., Emeryville, California
Lucas H Horan Eureka Therapeutics Inc., Emeryville, California
Bin Liu Eureka Therapeutics Inc., Emeryville, California
Su Yan Eureka Therapeutics Inc., Emeryville, California
Pei Wang Eureka Therapeutics Inc., Emeryville, California
Juan Diaz Eureka Therapeutics Inc., Emeryville, California
Lu Jin Eureka Therapeutics Inc., Emeryville, California
Yoko Nakano Eureka Therapeutics Inc., Emeryville, California
Javier F Morales Eureka Therapeutics Inc., Emeryville, California
Pengbo Zhang Eureka Therapeutics Inc., Emeryville, California
Lian-Xing Liu Eureka Therapeutics Inc., Emeryville, California
Binnaz K Staley Eureka Therapeutics Inc., Emeryville, California
Saul J Priceman Department of Immuno-oncology and Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, California.,Department of Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, California
Christine E Brown Department of Immuno-oncology and Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, California.,Department of Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, California
Stephen J Forman Department of Immuno-oncology and Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, California.,Department of Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, California
Vivien W Chan Eureka Therapeutics Inc., Emeryville, California
Cheng Liu Eureka Therapeutics Inc., Emeryville, California.

Collapse

An SL, Xiao T, Wang LM, Rong WQ, Wu F, Feng L, Liu FQ, Tian F, Wu JX. Prognostic Significance of Preoperative Serum Alpha- fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China. Asian Pac J Cancer Prev 2016;16:4421-7. [PMID: 26028108 DOI: 10.7314/apjcp.2015.16.10.4421] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open

Ji X, Shen Y, Sun H, Gao X. A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel. Tumour Biol 2016;37:10085-96. [DOI: 10.1007/s13277-016-4803-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Accepted: 01/06/2016] [Indexed: 01/16/2023] Open

Awan FM, Naz A, Obaid A, Ali A, Ahmad J, Anjum S, Janjua HA. Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach. PLoS One 2015;10:e0138913. [PMID: 26414287 PMCID: PMC4586137 DOI: 10.1371/journal.pone.0138913] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 09/06/2015] [Indexed: 12/14/2022] Open

Abstract

Hepatocellular carcinoma (HCC) is the world’s third most widespread cancer. Currently available circulating biomarkers for this silently progressing malignancy are not sufficiently specific and sensitive to meet all clinical needs. There is an imminent and pressing need for the identification of novel circulating biomarkers to increase disease-free survival rate. In order to facilitate the selection of the most promising circulating protein biomarkers, we attempted to define an objective method likely to have a significant impact on the analysis of vast data generated from cutting-edge technologies. Current study exploits data available in seven publicly accessible gene and protein databases, unveiling 731 liver-specific proteins through initial enrichment analysis. Verification of expression profiles followed by integration of proteomic datasets, enriched for the cancer secretome, filtered out 20 proteins including 6 previously characterized circulating HCC biomarkers. Finally, interactome analysis of these proteins with midkine (MDK), dickkopf-1 (DKK-1), current standard HCC biomarker alpha-fetoprotein (AFP), its interacting partners in conjunction with HCC-specific circulating and liver deregulated miRNAs target filtration highlighted seven novel statistically significant putative biomarkers including complement component 8, alpha (C8A), mannose binding lectin (MBL2), antithrombin III (SERPINC1), 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), alcohol dehydrogenase 6 (ADH6), beta-ureidopropionase (UPB1) and cytochrome P450, family 2, subfamily A, polypeptide 6 (CYP2A6). Our proposed methodology provides a swift assortment process for biomarker prioritization that eventually reduces the economic burden of experimental evaluation. Further dedicated validation studies of potential putative biomarkers on HCC patient blood samples are warranted. We hope that the use of such integrative secretome, interactome and miRNAs target filtration approach will accelerate the selection of high-priority biomarkers for other diseases as well, that are more amenable to downstream clinical validation experiments.

Collapse

Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer 2015;112:1911-20. [PMID: 26057582 PMCID: PMC4580401 DOI: 10.1038/bjc.2015.92] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 01/21/2015] [Accepted: 02/12/2015] [Indexed: 02/06/2023] Open

Abstract

Background:

Identification of tumour antigens is crucial for the development of vaccination strategies against hepatocellular carcinoma (HCC). Most studies come from eastern-Asia, where hepatitis-B is the main cause of HCC. However, tumour antigen expression is poorly studied in low-endemic, western areas where the aetiology of HCC differs.

Methods:

We constructed tissue microarrays from resected HCC tissue of 133 patients. Expression of a comprehensive panel of cancer-testis (MAGE-A1, MAGE-A3/4, MAGE-A10, MAGE-C1, MAGE-C2, NY-ESO-1, SSX-2, sperm protein 17), onco-fetal (AFP, Glypican-3) and overexpressed tumour antigens (Annexin-A2, Wilms tumor-1, Survivin, Midkine, MUC-1) was determined by immunohistochemistry.

Results:

A higher prevalence of MAGE antigens was observed in patients with hepatitis-B. Patients with expression of more tumour antigens in general had better HCC-specific survival (P=0.022). The four tumour antigens with high expression in HCC and no, or weak, expression in surrounding tumour-free-liver tissue, were Annexin-A2, GPC-3, MAGE-C1 and MAGE-C2, expressed in 90, 39, 17 and 20% of HCCs, respectively. Ninety-five percent of HCCs expressed at least one of these four tumour antigens. Interestingly, GPC-3 was associated with SALL-4 expression (P=0.001), an oncofetal transcription factor highly expressed in embryonal stem cells. SALL-4 and GPC-3 expression levels were correlated with vascular invasion, poor differentiation and higher AFP levels before surgery. Moreover, patients who co-expressed higher levels of both GPC-3 and SALL-4 had worse HCC-specific survival (P=0.018).

Conclusions:

We describe a panel of four tumour antigens with excellent coverage and good tumour specificity in a western area, low-endemic for hepatitis-B. The association between GPC-3 and SALL-4 is a novel finding and suggests that GPC-3 targeting may specifically attack the tumour stem-cell compartment.

Collapse

Liu G, Wang K, Li J, Xia Y, Lu L, Wan X, Yan Z, Shi L, Lau WY, Wu M, Shen F. Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy. J Gastroenterol Hepatol 2015;30:1405-11. [PMID: 25801981 DOI: 10.1111/jgh.12953] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/11/2015] [Indexed: 12/23/2022]

Khan I, Zakaria MK, Kumar M, Mani P, Chattopadhyay P, Sarkar DP, Sinha S. A novel placental like alkaline phosphatase promoter driven transcriptional silencing combined with single chain variable fragment antibody based virosomal delivery for neoplastic cell targeting [corrected]. J Transl Med 2015;13:254. [PMID: 26242403 PMCID: PMC4524171 DOI: 10.1186/s12967-015-0602-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 07/10/2015] [Indexed: 11/10/2022] Open

Abstract

BACKGROUND

Placental like alkaline phosphatase (PLAP), an oncofetal antigen, is highly expressed in germ cell, cervical, ovarian and several other tumour types but minimally in normal tissues [corrected]. The expression of a PLAP promoter based transcriptional unit following antigen mediated cell specific delivery is a possible approach for tumour targeting.

METHODS

PLAP promoter alone or in combination with NFκB DNA response elements was used for expressing shRNA targeting the long control region (LCR) of human papillomavirus (HPV)-16 oncogenes E6 and E7 via transcriptional gene silencing in PLAP expressing cervical cancer cell lines, SiHa and CaSki. This was packaged in a Sendai virus envelope incorporating a single chain variable fragment antibody (scFv) for antibody mediated targeting. Specificity and efficacy of the shRNA was assessed by studying the heterochromatization, down regulation of the HPV-16 E6/E7 genes and subsequent effects on their targets and cell growth properties.

RESULTS

Reduction of HPV-16 E6 and E7 expression by TGS led to the activation of the previously suppressed target genes of p53 (PUMA and NOXA) and Rb (cyclins A2 and E). Cell death was seen only in PLAP expressing HPV-16 infected SiHa and CaSki cells but not in the HPV-18 integrated HeLa and non-PLAP CHO cells. There was reduction in the enhancer associated transcripts of the long control region (LCR) of HPV-16 E6/E7 genes. Also, an increase in the enrichment of dimethylated histone three lysine nine (H3K9Me2) and trimethylated histone three lysine twenty-seven (H3K27Me3) was observed by ChIP assay, which decreased upon trichostatin A treatment, indicating a possible mechanism for the heterochromatization of the target LCR region.

CONCLUSION

A combination of novel PLAP promoter and antibody based specificities has the potential for being developed as a possible therapeutic strategy for PLAP positive neoplasia.

Collapse

Zhang C, Li G. Role of alpha-fetoprotein in hepatitis B virus-induced hepatocellular carcinoma: Prospect in clinical application. Shijie Huaren Xiaohua Zazhi 2015;23:3171-3181. [DOI: 10.11569/wcjd.v23.i20.3171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open

Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ, Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR, Xiang BD. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: Propensity score analysis. World J Gastroenterol 2015;21:4627-4634. [PMID: 25914472 PMCID: PMC4402310 DOI: 10.3748/wjg.v21.i15.4627] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 12/10/2014] [Accepted: 01/16/2015] [Indexed: 02/06/2023] Open

Zhang C, Chen X, Liu H, Li H, Jiang W, Hou W, McNutt MA, Lu F, Li G. Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm. Int J Cancer 2015;137:1818-29. [PMID: 25846475 DOI: 10.1002/ijc.29548] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2015] [Revised: 03/17/2015] [Accepted: 03/24/2015] [Indexed: 12/14/2022]

Fernekorn U, Hampl J, Weise F, Klett M, Läffert A, Friedel K, Schober A. Microfluidic 3D HepG2 cell culture: Reproducing hepatic tumor gene and protein expression in in vitro scaffolds. Eng Life Sci 2015. [DOI: 10.1002/elsc.201400083] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open

Toro A, Ardiri A, Mannino M, Arcerito MC, Mannino G, Palermo F, Bertino G, Di Carlo I. Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. BMC Surg 2014;14:40. [PMID: 24993566 PMCID: PMC4107750 DOI: 10.1186/1471-2482-14-40] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2013] [Accepted: 06/27/2014] [Indexed: 12/18/2022] Open

Yu Y, Li X, Zhou L, Dou KF, Li XL, Ruan B, Zhang ZC, Dai B, Wang JL, Yang XS, Wang DS. Clinical significance of expression of microRNA-34a and Notch1 in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014;22:1943-1952. [DOI: 10.11569/wcjd.v22.i14.1943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open

Abstract

AIM: To detect the expressions of microRNA-34a and Notch1 in hepatocellular carcinoma (HCC) and to explore their relationships with HCC occurrence and development and the clinical and pathological features of HCC.

METHODS: Real-time RT-PCR and immunohistochemistry were used to detect the expression of microRNA-34a and Notch1 protein in 132 HCC tissues, matched tumor-adjacent tissues and 49 normal liver tissues, respectively.

RESULTS: The expression of microRNA-34a in HCC tissues were significantly lower than that in tumor-adjacent tissues (P = 0.003) and normal liver tissues (P < 0.001). The expression of microRNA-34a in HCC tissues with metastasis was significantly lower than that in HCC tissues without metastasis (P = 0.014). The expression of Notch1 was significantly higher in HCC tissues than in tumor-adjacent tissues (P = 0.001) and normal liver tissues (P < 0.001). The expression of Notch1 in HCC tissues with metastasis was significantly lower than that in HCC tissues without metastasis (P = 0.008). The expression of microRNA-34a was negatively correlated with that of Notch1 in HCC and tumor-adjacent tissues (r = -0.259, P = 0.003; r = -0.274, P = 0.002). The expression of microRNA-34a and Notch1 in HCC had no correlation with patient age, gender, liver cirrhosis, tumor site, viral hepatitis, or AFP (P > 0.05 for all), but was closely correlated with tumor malignancy, tumor size, lymph node metastasis, tumor number, infiltration depth, and TNM stage (P < 0.05 for all). The 3-year survival rate in the group with low expression of microRNA-34a and high expression of Notch1 (11.3%) was significantly lower than that in the group with high expression of microRNA-34a and low expression of Notch1 (34.7%)(χ² = 38.163, P = 0.011).

CONCLUSION: The expression of microRNA-34a is significantly down-regulated in HCC tissues, which may reversely regulate its target protein Notch1. Detecting the expression of microRNA-34a and Notch1 in HCC had a potential significance for diagnosis, therapy and prognosis of HCC.

Collapse

Wang SS, Li H, Li G. Molecular structure and biological function of alpha-fetoprotein. Shijie Huaren Xiaohua Zazhi 2014;22:1487-1494. [DOI: 10.11569/wcjd.v22.i11.1487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open

Molecular mechanisms underlying antiproliferative and differentiating responses of hepatocarcinoma cells to subthermal electric stimulation. PLoS One 2014;9:e84636. [PMID: 24416255 PMCID: PMC3885594 DOI: 10.1371/journal.pone.0084636] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Accepted: 11/15/2013] [Indexed: 11/19/2022] Open

Ma WJ, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol 2013;11:212. [PMID: 23981851 PMCID: PMC3844510 DOI: 10.1186/1477-7819-11-212] [Citation(s) in RCA: 127] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2013] [Accepted: 08/05/2013] [Indexed: 02/06/2023] Open

Abstract

BACKGROUND

To investigate the prediction value of preoperative serum alpha-fetoprotein (AFP) level for the prognosis of hepatocellular carcinoma (HCC), by comparing pathological characteristics, recurrence rate and survival rate after hepatectomy.

METHODS

108 cases of HCC patients who received liver resection in our hospital from 2005 to 2011 were enrolled in this study. According to preoperative serum AFP level, the patients were divided into AFP ≤ 20 ng/mL group, AFP 20 to 400 ng/mL group and AFP > 400 ng/mL group, and the clinicopathological and cytopathological features were compared. All the patients were followed up for 24 months, the postoperative recurrence rates and survival rates were compared and analyzed, and the risk factors for HCC postoperative survival rate were studied by multifactor regression analysis.

RESULTS

Of the 108 cases of HCC patients, there were 42 cases in AFP ≤20 ng/mL group, 28 cases in AFP 20-400 ng/mL group and 39 cases in AFP > 400 ng/mL group. It was shown that cell differentiation degrees (χ² = 20.198, P = 0.000) and microvascular invasion rates (χ² = 20.358, P = 0.000) were significantly different among the three groups. The AFP ≤ 20 ng/mL group showed higher cell differentiation degrees and significantly lower microvascular invasion rates compared to the other groups (P < 0.05). The follow-up data showed that postoperative 2-year recurrence rate (χ² = 6.164, P = 0.046), 18-month survival rate (χ² = 7.647, P = 0.022) and 24-month survival rate (χ² = 6.725, P = 0.035) of the three groups were significantly different, and we found that the AFP ≤ 20 ng/mL group had lower postoperative 2-year recurrence rate, and higher 18-month survival rate and 24-month survival rate than the other two groups (P <0.05). Multiple logistic regression analysis indicated that tumor diameter (≥ 5 cm) and preoperative serum AFP level (> 400 ng/mL) were closely correlated with HCC postoperative survival rate (P <0.05).

CONCLUSIONS

It is shown that preoperative serum AFP level has considerable predictive value for the malignant feature and prognosis of HCC. It is suggested that HCC patients with no contraindication of operation and serum AFP ≤ 20 ng/mL can benefit most from primary treatment of hepatectomy. While HCC patients with serum AFP higher than 20 ng/mL need comprehensive therapy besides surgical resection and close follow up.

Collapse

Alpha-fetoprotein contributes to THP-1 cell invasion and chemotaxis via protein kinase and Gi-protein-dependent pathways. Mol Cell Biochem 2013;379:283-93. [PMID: 23615710 DOI: 10.1007/s11010-013-1650-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Accepted: 04/11/2013] [Indexed: 12/17/2022]

Teryukova NP, Blinova GI, Ivanov VA. Zajdela hepatoma cells cultured in vitro. ACTA ACUST UNITED AC 2013. [DOI: 10.1134/s1990519x13030127] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]

Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: A literature review. World J Gastroenterol 2013;19:321-7. [PMID: 23372352 PMCID: PMC3554814 DOI: 10.3748/wjg.v19.i3.321] [Citation(s) in RCA: 124] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Revised: 07/16/2012] [Accepted: 08/14/2012] [Indexed: 02/06/2023] Open

Cheng MR, Li Q, Wan T, He B, Han J, Chen HX, Yang FX, Wang W, Xu HZ, Ye T, Zha BB. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol 2012;18:6076-87. [PMID: 23155336 PMCID: PMC3496884 DOI: 10.3748/wjg.v18.i42.6076] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2012] [Revised: 07/18/2012] [Accepted: 07/28/2012] [Indexed: 02/06/2023] Open

Abstract

AIM: To observe the curative effect of galactosylated chitosan (GC)/5-fluorouracil (5-FU) nanoparticles in liver caner mice and its side effects.

METHODS: The GC/5-FU nanoparticle is a nanomaterial made by coupling GC and 5-FU. The release experiment was performed in vitro. The orthotropic liver cancer mouse models were established and divided into control, GC, 5-FU and GC/5-FU groups. Mice in the control and GC group received an intravenous injection of 200 μL saline and GC, respectively. Mice in the 5-FU and GC/5-FU groups received 200 μL (containing 0.371 mg 5-FU) 5-FU and GC/5-FU, respectively. The tumor weight and survival time were observed. The cell cycle and apoptosis in tumor tissues were monitored by flow cytometry. The expression of p53, Bax, Bcl-2, caspase-3 and poly adenosine 50-diphosphate-ribose polymerase 1 (PARP-1) was detected by immunohistochemistry, reverse transcription-polymerase chain reaction and Western blot. The serum blood biochemical parameters and cytotoxic activity of natural killer (NK) cell and cytotoxicity T lymphocyte (CTL) were measured.

RESULTS: The GC/5-FU nanoparticle is a sustained release system. The drug loading was 6.12% ± 1.36%, the encapsulation efficiency was 81.82% ± 5.32%, and the Zeta potential was 10.34 ± 1.43 mV. The tumor weight in the GC/5-FU group (0.4361 ± 0.1153 g vs 1.5801 ± 0.2821 g, P < 0.001) and the 5-FU (0.7932 ± 0.1283 g vs 1.5801 ± 0.2821 g, P < 0.001) was significantly lower than that in the control group; GC/5-FU treatment can significantly lower the tumor weight (0.4361 ± 0.1153 g vs 0.7932 ± 0.1283 g, P < 0.001), and the longest median survival time was seen in the GC/5-FU group, compared with the control (12 d vs 30 d, P < 0.001), GC (13 d vs 30 d, P < 0.001) and 5-FU groups (17 d vs 30 d, P < 0.001). Flow cytometry revealed that compared with the control, GC/5-FU caused a higher rate of G0-G1 arrest (52.79% ± 13.42% vs 23.92% ± 9.09%, P = 0.014 ) and apoptosis (2.55% ± 1.10% vs 11.13% ± 11.73%, P < 0.001) in hepatic cancer cells. Analysis of the apoptosis pathways showed that GC/5-FU upregulated the expression of p53 at both the protein and the mRNA levels, which in turn lowered the ratio of Bcl-2/Bax expression; this led to the release of cytochrome C into the cytosol from the mitochondria and the subsequent activation of caspase-3. Upregulation of caspase-3 expression decreased the PARP-1 at both the mRNA and the protein levels, which contributed to apoptosis. 5-FU increased the levels of aspartate aminotransferase and alanine aminotransferase, and decreased the numbers of platelet, white blood cell and lymphocyte and cytotoxic activities of CTL and NK cells, however, there were no such side effects in the GC/5-FU group.

CONCLUSION: GC/5-FU nanoparticles can significantly inhibit the growth of liver cancer in mice via the p53 apoptosis pathway, and relieve the side effects and immunosuppression of 5-FU.

Collapse

Cheng M, He B, Wan T, Zhu W, Han J, Zha B, Chen H, Yang F, Li Q, Wang W, Xu H, Ye T. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One 2012;7:e47115. [PMID: 23077553 PMCID: PMC3471936 DOI: 10.1371/journal.pone.0047115] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Accepted: 09/12/2012] [Indexed: 12/13/2022] Open

Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol 2012;39:410-33. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Citation(s) in RCA: 122] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]

Emre S, Umman V, Rodriguez-Davalos M. Current concepts in pediatric liver tumors. Pediatr Transplant 2012;16:549-63. [PMID: 22554057 DOI: 10.1111/j.1399-3046.2012.01704.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]